CTFH and Insilico Medicine embark on USD 200m AI novel drug discovery deal

China-based Jiangsu Chia Tai Fenghai Pharmaceutical Co.Ltd. (CTFH) has entered into an artificial intelligence (AI) technology development service agreement with Hong Kong-headquartered Insilico Medicine, encompassing complex and difficult drugs traditionally nigh-impossible to design. The partnership, designed to ramp up the treatment of triple negative breast cancer patient and other developments, includes an upfront payment, milestone payments and sales performance rewards, amounting to USD 200 million upon successful cooperation.

CTFH, a foreign-funded holding company born out of the merging of Charoen Pokphand Group, a.k.a. C.P. Group and Jiangsu Nongken Group Co., Ltd (GBI translation), develops various preparations and active pharmaceutical ingredients (APIs) covering infection, respiratory, digestive, cardiovascular and cerebrovascular, neuropsychiatric, special medicine, and anti-tumor, among other treatment fields.

Meanwhile, Insilico Medicine, an AI-enabled drug discovery firm, boasts of a business presence covering US, UK, China, Russia, South Korea, and Nigeria.


Related news
China’s National Medical Products Administration (NMPA) released a notification indicating that 15 drug filings have been requested to carry out self-auditing of trial data prior to onsite inspections.
Chai Tai Fenghai Pharmaceutical recently broke ground on a new facility in Dafeng, Jiangsu Province, with a total planned investment of RMB 230 million.
Recent news
Zulema Tomás Gonzáles, head of Peru’s Ministry of Health (MINSA), this week announced that she will pressure President Martín Vizcarra to approve through emergency decrees two draft laws aimed at improving health access.
Bayer Consumer Health opened its first Asia-Pacific R&D center, located in Qidong, Jiangsu, China.
Guillaume Corpart, managing director of hospital statistics firm Global Health Intelligence, said during an interview with the Mexico Health Review that recent changes in Mexico’s public sector are putting pressure on drug and medical supplies providers.
Shenzhen-based Ionova Life Science Co., Ltd announced a successful RMB 126 million (USD 17.8 million) in a Series A financing round, led by Lilly Asia Ventures, with DYEE Capital participating.
Swiss major Novartis and Brazil’s Oswaldo Cruz Foundation (Fiocruz) signed a memorandum of understanding (MoU) to cooperate in research and development (R&D) and education projects to combat neglected diseases such as Hansen's disease (HD), Chagas disease, malaria, and sickle cell disease.
China Grand Pharmaceutical and Healthcare Holdings Ltd (CGP) is moving to take a sizeable stake in US-headquartered biotech OncoSec Medical Inc. An agreement has been reached for CGP to acquire 44.2% of OncoSec for USD 25 million, subject to shareholder approval, with an option to fully buy out the company within 12 months.
  • 1571120805603
  • China
The Implementation Plan for the “Two Invoices” System in Public Medical Institutions Drug Procurement” was jointly released by several ministries in Shandong, led by the Health Commission bureau, as well as the Development and Reform Commission, the Healthcare Security Administration, and others.
Analytics Snapshot

Analytics Snapshot